Quemliclustat is under clinical development by Arcus Biosciences and currently in Phase II for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase II drugs for Pancreatic Ductal Adenocarcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Quemliclustat LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Quemliclustat is under development for the treatment of solid tumors including metastatic castrate resistant prostate cancer (mCRPC), non-small cell lung cancer, metastatic adenocarcinoma of the pancreas, melanoma, gastric cancer, pancreatic ductal adenocarcinoma and bile duct cancer (Cholangiocarcinoma) The drug candidate is administered through intravenous and oral route. It acts by targeting CD73.
Arcus Biosciences overview
Arcus Biosciences operates as a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies by leveraging underexploited biological opportunities. Its product pipeline includes AB928, a selective dual antagonist of the adenosine receptors known as A2aR and A2bR in combination with anti-PD-1 antibody (AB122) and chemotherapy is used for the treatment of metastatic triple-negative breast cancer or ovarian cancer and advanced malignancies; AB122, an anti-PD-1 antibody targeting cancer; AB154, an anti-TIGIT antibody; and AB680, a CD73 inhibitor against solid tumors. Arcus Biosciences is headquartered in Hayward, California, the US.
For a complete picture of Quemliclustat’s drug-specific PTSR and LoA scores, buy the report here.